NEW YORK, NY — (Marketwire) — 04/19/12 — is pleased to announce that (OTCBB: ACCP) will be presenting at our 9th Annual Small Cap Equity Conference May 1, 2012. The Conference will take place at the New York Athletic Club, New York City. To request additional information or to , contact at 212-779-2971 or visit .
. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access- products include (), which has received FDA marketing clearance for the management of patients with mucositis, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and , a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including and , its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at .
Contact:
Taglich Brothers
Karen Payne
Symposia Events
212-779-2971